Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis
| Autor: | Kaita Sugiyama, Natsumi Ikumi, Yoshihiro Matsukawa, Masami Takei, Hidetaka Shiraiwa, H. Inomata, Y. Nagasawa, H. Karasawa, Mitsuhiro Iwata, Noboru Kitamura, Takamasa Nozaki |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Osteoporosis 030209 endocrinology & metabolism Gastroenterology Bone resorption Bone remodeling 03 medical and health sciences 0302 clinical medicine Rheumatology Bone Density Internal medicine medicine Steroid-induced osteoporosis Humans Femur Prospective Studies Adverse effect Tokyo Glucocorticoids Aged 030203 arthritis & rheumatology Bone mineral Lumbar Vertebrae Bone Density Conservation Agents Diphosphonates business.industry Imidazoles Middle Aged medicine.disease Endocrinology Treatment Outcome Gastrointestinal disorder Rheumatoid arthritis Female business Biomarkers Osteoporotic Fractures |
| Zdroj: | International journal of rheumatic diseases. 21(4) |
| ISSN: | 1756-185X |
| Popis: | Objectives Minodronic acid hydrate, an oral bisphosphonate, has a greater inhibitory effect on bone resorption than do other approved drugs; however, this has been studied only in patients with primary osteoporosis. Here, we administered minodronic acid hydrate to patients with steroid-induced osteoporosis who have been treated with steroids for rheumatoid arthritis or other collagen diseases, and the efficacy and safety of minodronic acid hydrate were prospectively investigated. Methods Twenty-five patients treated in our rheumatology clinic received minodronic acid hydrate 1 mg/day. The changes in bone mineral density (BMD) and bone turnover markers were investigated at 3 and 6 months, and adverse events, including the presence or absence of an incident osteoporotic fracture, were examined over a period of 6 months. Results Percent changes in BMD of the lumbar spine and femur significantly increased. The values of bone turnover markers significantly decreased. There were no patients with a radiographically apparent incident fracture. Adverse events included toothache for which the patient discontinued the treatment and three cases of gastrointestinal disorder that did not lead to discontinuation, and thus minodronic acid hydrate was well tolerated. Conclusions Here, we show that minodronic acid hydrate is effectively and safely used for treatment of steroid-induced osteoporosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text